+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of Paget's disease of bone with alendronate



Treatment of Paget's disease of bone with alendronate



Bone 24(5 Suppl): 59s-61s



In summary, the clinical efficacy studies provide clear evidence that treatment with oral alendronate markedly suppresses bone turnover and produces clinical improvement in pagetic patients. Serum alkaline phosphatase was greatly decreased by treatment, and the response to alendronate was superior to that observed for currently available therapies such as etidronate and calcitonin, which usually reduce alkaline phosphatase, on average, by 40%-50%. Alendronate also markedly reduced urinary resorption markers and induced radiologic improvement of pagetic osteolysis. A majority of alendronate-treated patients normalized their serum alkaline phosphatase by month 6. This observation is likely to be relevant to the duration of response to treatment, as previous studies have shown that the degree of suppression of alkaline phosphatase after antiresorptive treatment correlates with the duration of remission. Therefore, patients who responded to treatment with alendronate, especially those who normalized their alkaline phosphatase levels, are likely to maintain the biochemical remission for several years. Indeed, preliminary unpublished data seem to indicate that alendronate is capable of producing long-term biochemical remission in the majority of patients. In addition to its efficacy, the safety and tolerability profile of alendronate 40 mg/day was very favorable and, overall, comparable to that of placebo.

(PDF emailed within 0-6 h: $19.90)

Accession: 035980552

Download citation: RISBibTeXText

PMID: 10321931

DOI: 10.1016/s8756-3282(99)00063-0


Related references

Alendronate in the treatment of Paget's disease of bone. Bone (New York) 20(3): 263-271, 1997

The treatment with alendronate in hemifacial spasm associated with Paget's disease of bone. Clinical Neurology & Neurosurgery 102(1): 48-51, March, 2000

Paget's disease of bone--treatment with alendronate, calcium and calcitriol. Vnitrni Lekarstvi 45(10): 602-605, 2000

Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 15(4): 415-417, 1994

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. Journal of Clinical Endocrinology and Metabolism 81(3): 961-967, 1996

A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone. Bone 34(4): 747-754, 2004

Five-year follow-up of Japanese patients with Paget's disease of the bone after treatment with low-dose oral alendronate: a case series. Journal of Medical Case Reports 4(): 166-166, 2010

Low dose of oral alendronate decreases bone turnover in Japanese patients with Paget's disease of bone. Journal of Bone and Mineral Metabolism 23(4): 333-336, 2005

The effects of intravenous alendronate in Paget's disease of bone. Journal of Bone and Mineral Research 10(7): 1094-1100, 1995

Effects of five daily 1 h infusions of alendronate in Paget's disease of bone. Journal of Bone and Mineral Research 7(1): 81-87, 1992

Asymptomatic Paget's disease of bone in a 62-year-old Nigerian man: three years post-alendronate therapy. Endocrinology, Diabetes & Metabolism Case Reports 2016(): 160005-160005, 2016

Duration of the effects of intravenous alendronate in postmenopausal women and in patients with primary hyperparathyroidism and Paget's disease of bone. Bone and Mineral 25(2): 75-82, 1994